Diseases [C] » Digestive System Diseases [C06] » Liver Diseases » Liver Cirrhosis
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Fibrosis » Liver Cirrhosis
Description
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules. MeSH
Hierarchy View
Subtype Terms (3)
Liver Cirrhosis, Alcoholic
12 drugs (5 approved, 7 experimental)
Liver Cirrhosis, Biliary
66 drugs (33 approved, 33 experimental)
Liver Cirrhosis, Experimental
3 approved drugs
Approved Indicated Drugs (3)
Phase 3 Indicated Drugs (47)
Phase 2 Indicated Drugs (50)
Phase 1 Indicated Drugs (24)
Other Experimental Indicated Drugs (49)
Organization Involved with Phase 4 Indications (125)
American Association for the Study of Liver Diseases Foundation
Asian Institute of Gastroenterology
Asian Institute Of Medical Sciences
Asian-Pacific Alliance of Liver Disease, Beijing
Azienda Ospedaliera San Camillo Forlanini
Badalona Hospital Germans Trias i Pujol
China Academy of Chinese Medical Sciences
Eastern Hepatobiliary Surgery Hospital
Fifth Hospital of Shijiazhuang City
German Federal Ministry of Education and Research
Gottfried Wilhelm Leibniz Universität Hannover
Govind Ballabh Pant Institute of Postgraduate Medical Education and Research
Hannover Clinical Trial Center GmbH
Huai'an No. 4 People's Hospital
Huazhong University of Science and Technology
Hubei University of Chinese Medicine
Icahn School of Medicine at Mount Sinai
Institute of Liver and Biliary Sciences, India
Jining NO.1 People 's Hospital
Katholieke Universiteit Leuven
Medical University of South Carolina
People's Liberation Army of China
Qilu Hospital of Shandong University
Samil Pharmaceutical Co., Ltd.
Second Military Medical University
Second People 's Hospital of Liaocheng
Shandong University of Traditional Chinese Medicine
Shanghai University of Traditional Chinese Medicine
Shenzhen Third People's Hospital
Taipei Veteran General hospital
The Fifth People's Hospital of Suzhou
Organization Involved with Phase 3 Indications (92)
All India Institute of Medical Sciences
Assistance Publique - Hôpitaux de Paris
Associazione Italiana per la Ricerca sul Cancro
Bambino Gesù Hospital and Research Institute
Beijing Trendful Kangjian Medical Information Consulting Limited Company
Casa Sollievo della Sofferenza IRCCS
Case Western Reserve University
F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
Federal University of Rio de Janeiro
Fondo de Investigacion Sanitaria
French National Agency for Research on AIDS and Viral Hepatitis
Hospital Universitario Virgen Macarena
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Institute Of Cardiology & Internal Diseases, Kazakhstan
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Istituto Clinico Humanitas - Rozzano (MI), Italy
Nanyang Technological University
National Cancer Institute (NCI)
National Center for Research Resources (NCRR)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
National University of Singapore
Pavol Jozef Safarik University
Postgraduate Institute of Medical Education and Research
Rio de Janeiro State University
Sociedad Andaluza de Enfermedades Infecciosas
Society for the Study of Liver Diseases, Chandigarh ( India )
Tianjin Second People's Hospital
Translational Research Informatics Center, Kobe, Hyogo, Japan
Organization Involved with Phase 2 Indications (120)
A2 Healthcare Taiwan Corporation
ADS AIPHIA Development Services AG
Bombay Hospital & Medical Research Center
Catholic University of Sacred Heart, Rome
Centre for Liver Research & Diagnostics, Hyderabad
Centro de Investigación Biomédica en Red (CIBER)
Chinese Academy of Medical Sciences
Chinese People's Armed Police Forces
CIHR Canadian HIV Trials Network
Department of Health, United Kingdom
Federal University of Minas Gerais
General Hospital of Chinese Armed Police Forces
Grupo Mexicano para el Estudios de las Enfermedades Hepaticas
Gwo Xi Stem Cell Applied Technology Co., Ltd.
Ho Chi Minh City University of Medicine and Pharmacy
Hoosier Cancer Research Network
IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest
Japan Agency for Medical Research and Development
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
Melaka Manipal Medical College
National Center for Global Health and Medicine
National Institute for Health Research, United Kingdom
Niigata University Medical & Dental Hospital
Rajasthan University of Health Sciences
Organization Involved with Phase 1 Indications (29)
Organization Involved with Other Experimental Indications (40)
Autonomous University of Madrid
Canadian Institutes of Health Research (CIHR)
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Hospital of South West Jutland
Instituto Mexicano del Seguro Social
Instituto Nacional de Ciencias Medicas de Nutricion
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
